Company Filed Second Patent Application to Extend Core Technology Applications Murrieta Genomics is pleased to announce that U.S. Patent and... View Article
“Our first product is a kit for the purification and isolation of nucleic acids from plasma that we believe will transform the genomic industry.”
This is going to be fun!
On Friday, January 29th 2021 an article about Murrieta Genomics and our wholly owned subsidiary, SimplSEQ, was published by GenomeWeb.... View Article
Murrieta Genomics was recently named as a “company to watch” by The Healthcare Insights, a medical publication that discusses developments... View Article
Murrieta Genomics has announced that its wholly owned subsidiary, SimplSeq Inc., has filed a new patent application for simplified sample... View Article
Life Science Nation provides an incredibly important service to early stage life science companies by connecting them with products, services and capital.
John Powers, President of Murrieta Genomics and CEO of SimplSeq, our wholly owned subsidiary, was interviewed recently on Beyone with... View Article
Murrieta Genomics, the provider of genomics services and a launch pad for genomic sequencing startups, will be hosting a lunch... View Article
Murrieta Genomics, the provider of genomics services and a launch pad for genomic sequencing startups, has signed a tenancy agreement... View Article